Momenta Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2001)
Status: Acquired by Johnson and Johnson (2020)

Organization Overview

First Clinical Trial
2007
NCT00543400
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Momenta Director of Clinical Operations | Momenta Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Hemolytic (Phase 3)

Anemia, Hemolytic, Autoimmune (Phase 3)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Edema (Phase 3)

Hemolysis (Phase 3)

Macular Edema (Phase 3)

Muscle Weakness (Phase 2)

Myasthenia Gravis (Phase 2)

Myocardial Ischemia (Phase 2)

Pancreatic Neoplasms (Phase 2)

Psoriasis (Phase 3)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 11